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Abstract. The PDGFs are a family of molecules as-
sembled as disulfide-bonded homo- and heterodimers
from two distinct but highly homologous polypeptide
chains (PDGF-A and PDGF-B). Two PDGF A-chain
transcripts, which arise from alternative usage of the
69-bp exon 6 and exon 7, give rise to two forms of
PDGF-A . In spite of the conservation of two PDGF
A-chain forms over at least 350 million years, no dif-
ferences in their biological activities have been identi-
fied. We have investigated the activity of the sequence
encoded by the alternatively spliced exon 6 of the
PDGF A-chain (peptide AL). Addition of peptide AL at
10-s-10~M to cultured endothelium and smooth mus-
cle induced a dose-dependent, 3-20-fold increase in
PDGF in conditioned media within 30 min. Peptide
AL had no detectable effect on A- or B-chain transcript
C
ONSERVATION of the two highly homologous A- and
B-chains of PDGF and the alternative usage of exon
6 ofthe A-chain over at least350 million years of evo-
lution (Mercola et al., 1988 ; Matoskova et al., 1989), sug-
gest that each of the protein products may have different
functional roles. The existence of the A- and B-chains of
PDGF is partly explained by recent data establishing the ex-
istence of two distinct cell-surface PDGF receptors, one that
binds either the A- or B-chain (termed the ot-subunit) and the
other that only binds the B-chain (the a-subunit) (Hart et al .,
1988; Heldin et al., 1988, 1989; Seifert et al., 1989; Matsui
et al., 1989a,b). The two receptor subunits are expressed in
differing numbers and proportions on different cell types and
are differentially regulated. As a consequence, the capacity
of the different dimers of PDGF to induce chemotaxis and
mitogenesis, as well as a number of other critical cell func-
tions, depends on both the type of PDGF dimer present and
the relative number and proportion of receptor subunits on
the respondingcell (Seifert et al., 1989 ; Ferns et al., 1990).
However, no major differences have been demonstrated in
receptor subunit binding or in biological activity for the two
alternative forms of the PDGF A-chain (Beckmann et al.,
1988; Ostman et al., 1989).
In the course of attempting to develop antibodies specific
to each of the two distinct carboxy-termini (COOH-termini)
of the long and short forms of the PDGF A-chain, we ob-
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levels, and decrease in culture temperature did not pre-
vent rapid release of PDGF. In human umbilical vein
endothelial cells treated with peptide AL, the PDGF
released was principally PDGF-BB, while in smooth
muscle cells it was primarily PDGF-AA . The capacity
to induce release of PDGF is shared by the homolo-
gous peptide encoded by exon 6 of the B-chain of
PDGF. Binding studies and cross-linking analysis are
consistent with a charge-based association of exon 6
sequences with membrane- and matrix-associated he-
paran-sulfate proteoglycans. We hypothesize that trans-
lation of exon 6 of the A- or B-chain of PDGF results
in compartmentalization of these forms of PDGF with
HS-PG, whereas forms lacking this sequence would be
soluble and diffuse.
served that immunization with a peptide representing the se-
quence unique to the alternatively spliced exon 6 (peptide
AL) resulted in antibodies that recognized the unrelated se-
quence of the COOH-terminus of the short form of the
PDGF A-chain. These antibodies also recognized mature
PDGF, although less well, that contained no sequences ho-
mologous with the exon 6 sequence. Although the basis of
the response in these animals to peptide AL is unclear, we
pursued the hypothesis that peptide AL may induce the re-
lease of endogenous PDGF. As demonstrated in this report,
peptide AL induces a temperature-independent release of
PDGF from cultured human umbilical vein endothelial cells
(HUVECs)' and smooth muscle cells (SMCs) . On the basis
of our observations, we propose a model in which the pres-
ence of exon-6-encoded sequences results in compartmen-
talization of these specific forms of PDGF on cell- and ma-
trix-associated heparan-sulfate proteoglycan (HS-PG) while
the alternatively spliced form of PDGF A-chain, lacking
exon-6-encoded sequences, is secreted. Such differential
compartmentalization could determine whether PDGF acts
principally as a growth factor involved in cell-cell interac-
tions, or whether it acts in a broader context as a paracrine
growth factor.
1. Abbreviations used in thispaper: HS-PG, heparan-sulfate proteoglycan;
HUVEC, human umbilical vein endothelial cell; RRA, radioreceptorassay;
SMC, smooth muscle cell.
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Peptides
The peptides used in our experiments were synthesized by the Chemical
Synthesis Facility ofthe Howard Hughes Medical Institute at the University
of Washington. They were synthesized using standard automated solid
phase synthesis chemistry which is discussed indetail in Stewart and Young
(1984). After synthesis, the purity ofthe synthesized peptides was assessed
by HPLC using a C18-reverse phase column.
Immunization ofRabbitsandEvaluation ofAntisera
Thepeptides were coupledtokeyhole limpethemocyanin (Calbiochem, San
Diego, CA) through a cysteine added at the amino-terminal (NH2-terminal)
end of each peptide (Liu et al., 1979) using m-maleimidobenzoyl-N-hy-
droxysuccinimide ester (Calbiochem, San Diego, CA). Rabbits were im-
munized with 200 Wg of coupled peptide per injection, administered sub-
cutaneously in RIBI adjuvant (RIBI Immunochem Research, Hamilton,
MT) 2, 3, and 8 wk after the initial injection. Plasma was collected from
the animals by collection into sodium citrate and centrifugation to remove
the cells. Plasma samples were evaluated in an ELISA in which peptides
(250 Ag/ml, 100,ul/well)or dimeric forms ofPDGF (25 ng/ml, 100,ul/well)
were coated on 96-well multiwell inununoplate (Nunc, Denmark) overnight
at 4°C. Different dilutions ofplasma were incubated with the coated trays
for 1 h at 37°C after blocking the plate with 10 mg/ml BSA. This was fol-
lowed by incubation with biotin-conjugated goat anti-rabbit IgG (Vector
Labs, Burlingame, CA), avidin-HRP (Vector Labs, Burlingame, CA), and
developed with o-phenylenediamine (SigmaChemical Co., St. Louis, MO)
as the color reagent.
Cell Culture
Cultures ofhuman arterial SMC were grown from explants ofaortic media
and maintained in Dulbecco-Vogt medium (Gibco Laboratories, Lawrence,
MA) supplemented with 10% FBS (Hyclone, Logan, UT) . HUVECs were
obtained by collagenase digestion of umbilical cords as previously de-
scribed (Wall et al., 1978) and maintained in RPMI-1640 (Whittaker Bio-
products, Walkersville, MD) containing 18% adult BSA (Hyclone, Logan,
UT), 2 .4% HUVEC growth factor (Gospodarowicz et al., 1983), and 60
pg/ml heparin (Sigma Chemical Co.). Dishes were coated with 1% gelatin
(Sigma Chemical Co.) before plating the HUVEC. 24 h before initiation of
experiments, the media were changed to 1% plasma-derived serum or 5%
Carboxymethyl Sephadex fraction I (Raines and Ross, 1985) for the SMC
and HUVEC, respectively. At the time of initiation of experiments, fresh
medium was added to the cells along with increasing concentrations of the
peptides.
AssaysforPDGF
The levels ofPDGF in media collected from cell cultures were determined
by PDGF radioreceptor assay (RRA) on human skin fibroblasts using 125I-
PDGF-AB (Bower-Pope and Ross, 1985) or using PDGF ELISA specific
for different dimeric formsof PDGF The chain-specific ELISAs use a mAb
made to recombinant PDGF-AA, 127.2.2.2 (Hart et al., 1990), or a mAb
specific for a 25-amino-acid peptide located near the COOH-terminus of
the PDGF B-chain, PGF-007 (Shiraishi et al., 1989; Ross et al., 1990), in
combination with rabbit anti-PDGF antisera from animals immunized with
either recombinant PDGF-AA (aA) or PDGF-BB (aB) (Hart et al., 1990).
Western BlotAnalysisofPDGFReleased by PeptideAL
Concentrates of serum-free medium collections from cells treated with pep-
tide AL were concentrated in Centriprep microconcentrators (Amicon,
W.R. Grace and Co., Beverly, MA) and then separated on 15% SDS poly-
acrylamide gels (Laemmli, 1970). Samples were analyzed under non-
reduced and reduced conditions and transferred electrophoretically to
nitrocellulose (Schleicher & Schnell, Inc., Keene, NH) in 25 mM tris, 192
mM glycine, 20 % methanol, pH 8.3, for 16 h. For Western blot analysis,
the nonspecific binding was blocked by incubation with 1% BSA in TBS
for 1 h at room temperature with shaking, followed by incubation with
affinity-purifiedgoat anti-PDGF for90 min at room temperature. After four
washes with TBS, biotinylatedsecond antibody specific for theprimary an-
tibody (Vector Laboratories, Burlingame, CA) was added and incubated for
60 min followed by an additional four washes. The peroxidase conjugate
was developed with 0.03% H202, 0.074% DAB tetrachloride (Sigma
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Chemical Co.) in 0.05 M Tris-HCI, pH 7.25. The affinity-purified goat anti-
PDGF, which recognizes allchains ofPDGF, was preparedby repeated pas-
sage of DEAE-purified IgG over a column ofSepharose CL-4B (Pharmacia
Fine Chemicals, Piscataway, NJ) to which 400 ug of purified PDGF had
been coupled after cyanogen-bromide activation (March et al., 1974).
MetabolicLabeling Studies
Cultures of HUVEC were grown to confluence and six flasks (2 x 10,
cells per flask) were changedtocysteine-freemedia containing 5% carboxy-
methyl sephadex fraction I (Raines and Ross, 1985) for 3 h before addition
of 35S-cysteine. The cultures were labeled for 16 h with 100 ilCi/m135S-
cysteine (Amersham, 1,300 C/mmol). After 16 h, the culture media were
replaced with complete medium for 2 additional h and subsequently were
changed to Hepes-buffered media and incubated for 4 h at 4°. Three flasks
were treated with diluent and three flasks received 200 pg/ml peptide B24.
At the end of the incubation, the media was collected and the cells were
solubilized in 1% triton, 0.05% Tween-20, 0.5% deoxycholate in PBS. Me-
diaandcellpelletsweresubsequently incubated for 1 h at roomtemperature
with anti-PDGF-BB (mouse monoclonal 120.1.2.1; Hart et al., 1990) cou-
pled to Sepharose. In all cases, one half of the sample was incubated with
anti-PDGF-BB Sepharosepreincubated with 2 wg PDGF-BB. Afterremoval
of unbound supernatant, the gels were washed three times with PBS con-
taining 0.5% deoxycholate and 2.5 mg/ml BSA followedby two washes with
PBS containing 2.5 mg/mlBSA. Boundproteins were elutedwith 1 N acetic
acid and lyophilized for analysis by SDS-PAGE.
PeptideBindingStudies
Peptides were synthesized which contained a tyrosine residue added at the
NH2 terminus of peptide AL and B-chain residues 133-144 (assuming resi-
due 1 is the NH2-terminal serine in the mature B-chain) to allow iodination
ofthepeptides using iodobeads (Pierce Chemical Co., Rockford, IL) . Cells
were plated in 24-well cluster dishes and allowed to grow to confluence.
Binding studies were performed essentially as previously described for
PDGF (Bower-Pope and Ross, 1985). Briefly, binding studies were per-
formed with increasing concentrations of 1251-peptides on cells plated in
24-well trays (Costar, Cambridge, MA). Cultures were rinsed once with
cold PBS, incubated with 1 ml test solution in binding medium for 3 h at
4°C with continuous oscillatory mixing, rinsed three times with cold bind-
ing rinse, and the cell-bound 1251-peptides were solubilized with 1 ml 1%
Triton X-100 in distilled water for 4 min at room temperature. The wells
were subsequently washed with 1 ml 4 M urea in PBS to extract matrix-
associated peptides. Glycosaminoglycans usedfor competition studies were
heparin from porcine intestinal mucosa, heparan sulfate from bovine kid-
ney, chondroitin sulfate, type A from porcinecartilage, type B from porcine
skin, and type C from shark cartilage (Sigma Chemical Co.).
AmityCross-linkingStudies
1251-peptides at 1 Ag/ml were incubated with cells as described above in
peptide binding studies for 3 h at 4°C. After washing three times, the cells
were incubated with shaking for 10 min at 4°C with 1 mM Bis (sulfosuc-
cinimidyl) suberate (Pierce Chemical Co.) in PBS (250 141/well) made im-
mediately before use. Wells were subsequently incubated with 20 mM Tris,
0.15 M NaCl, pH 7.5, for 2 min at 4°C, rinsed twice with binding rinse,
drained, and then solubilized with SDS sample buffer (Laemmli, 1970) for
4 min with shaking at room temperature (200,ul/well). Before separation
on SDS-PAGE, aliquots of cross-linked samples were incubated without
further addition or in the presence of 1 U/ml heparinase (Sigma Chemical
Co.) and 5 MM CaC12 for 2 h at 37°C. At the end of the incubation, mer-
captoethanol was added to all samples (final concentration of5%), and the
samples were boiled and loaded on 5 % SDS-PAGE gels with a 3% stacking
gel. After SDS-PAGE, the gels were dried and exposed to Kodak X-Omat
film at -70°C.
Results
RabbitsImmunizedwith thePeptideEncoding
Exon 6 ofthePDGFA-ChainRecognize the Distinct
COOH-terminalSequence ofthe ShortForm
ofPDGFA-Chain
To further investigate the long (PDGF-AL) and short
(PDGF-As) forms of the PDGF A-chain, we attempted to
534make antibodies that would specifically recognize PDGF-
AL and PDGF-As . Peptides containing the predicted se-
quence of the alternative COOH-termini of the long and
short forms of the A -chain (Fig. 1 a) were synthesized and
injected into rabbits . Each of three rabbits(two shown in Fig.
1 b, numbers 1 and 2) injected with the peptide encoded by
exon 6 of the A-chain (peptide AL ) developed antibodies to
that peptide, butalso antibodies that recognized the distinct
Figure 1. Relative recognition of peptides andPDGF by rabbits im-
munizedwith peptides encoding distinct COOH-termini ofthe long
and short forms of the PDGF A-chain . (A) The indicated peptides
encoding the distinct COOH-termini of the long and short forms
ofthePDGF Achain were synthesized andcoupled to keyhole lim-
pethemocyanin for immunization of rabbits as described in experi-
mental procedures . The two forms of the mature PDGF A-chain
(boxedarea) arise from alternative usage of the69-bpexon 6 (gray
box) . Peptide AL is the sequence encoded by exon 6 (gray box),
while peptide A, contains sequence shared by the long and short
forms of the A-chainencoded by exon 5 and three unique residues
encoded by exon 7 (black box) . The B-chain contains C-terminal
"pro sequences (underlined sequence, no box), encoded by the
B-chainexon 6, that share significant homologies with A-chain exon
6 (indicated by asterisks) . A number of conservative substitutions
that wouldmaintain a similar charge distribution are also apparent
(indicated by crosses) . B-chain peptides synthesized for binding
andcompetition studies are indicatedby brackets. (B) ELISA data
obtained with four rabbits (numbers indicated inside bars) immu-
nized with peptideAL (rabbits 1 and 2, open bars) and peptide A,
(rabbits 3 and4, hatchedbars) . The indicated peptides (25 ng/well)
or different dimeric forms ofPDGF (2 .5 ng/well) were used to coat
96-well microtiter plates (Nunc), and the ELISA performed as de-
scribed in Materials and Methods. Plasma obtained from the im-
munized rabbits 7 d after the fourth injection of coupled peptide
were evaluated at dilutions of 1:800 for peptide AL , 1:200 for pep-
tide As , and 1:10 for the PDGF dimeric forms . The absorbance
observed with preimmuneplasma for each of the animalshas been
subtracted from the absorbance observedat the samedilution ofim-
mune plasma .
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peptide sequence of the short form of the A-chain (peptide
As) (Fig . 1 b) . Rabbits injected with peptideAL recognized
peptide As better than rabbits injected with peptide As
(numbers 3 and 4) . At very high serum concentrations, rab-
bits injected with peptide AL also recognized PDGF-AA
and PDGF-AB (which contain only the peptideAs 000H-
terminal sequence) and mature PDGF-BB (that contains
none of the homologous exon-6 "pro" sequence) . Sincepep-
tideAL and peptideAs are not homologous (Fig . 1 a), it is
unclear why rabbits injected with peptide AL recognized
the unrelated peptide as well as native human PDGF How-
ever, one possible explanation for these observations is that
injection of peptide AL induced release of endogenous
PDGF to whichthe rabbitsdeveloped antibodies . We, there-
fore, investigated the effects of the addition of peptide AL to
cultured HUVEC and SMC.
ThePeptide EncodingExon 6ofthePDGF
A-ChainInduces Release ofPDGFfrom Cultured
HUVEC andSMC
In both HUVEC and SMC, addition of the peptide encoded
by exon 6 at 10~M to 10-IM induces a dose-dependent in-
crease in thePDGF in the conditionedmedium2 hafterad-
dition of peptideAL (Fig. 2) . Although each of these cells
constitutively producesPDGF in culture, theamount present
in the medium following a 2-h incubation with the peptide
is the equivalent of 69 or 104 h of constitutive synthesis by
HUVEC and SMC, respectively. The kinetics of the 3-20-
fold increase in PDGF detected in the conditioned medium
were rapid in both cell types (Fig . 3) . A similar effect is not
induced by the addition of an 11-amino acid peptide that
codes for the COOH-terminal sequence of the spliced pep-
Figure 2 . The peptide encoding exon 6 ofPDGF A-chain induces
a dose-dependent release of PDGF activity from HUVEC and
SMC . The peptide encoding exon 6 of PDGF A-chain (peptide
AL ) was added to cultured HUVECand SMC at the indicated con-
centrations andthemedia were collected after2 h for the determi-
nation of the level of PDGF . PDGF levels were determined by
PDGF RRA (Bowen-Pope and Ross, 1985) and were normalized
to cell number (x10 6) . Thedose response data is representative of
three replicative experiments and two separate cell isolates for each
cell type . Media from the untreated cells were collected after24 h
dueto the lower levels ofPDGF secretion, andrepresent themean
of four separate collections which were normalized to the PDGF
production over 2 h .
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Figure 3 Peptide AL induces rapid and specific release of PDGF
from HUVEC and human arterial SMC. HUVEC (A) or human ar-
terial SMC (B) were cultured for varying periods of time in the
presence of 2 x 10-'M peptide AL (o), peptide A, (A), an 11-
amino acid peptide coding for the 00011-terminal sequence ofthe
short form of the A-chain, a combination of two basic peptides (0;
CVRKKPIFKKATVTLEDHLACK and HHRS; matched for mo-
lar concentrations of arginine and lysine in peptide AL), or diluent
(o; 10 mM acetic acid). At the indicated time period, after addi-
tion ofthe peptides, the media was collected and cell number was
determined. The PDGF content of the collected media was deter-
mined by PDGF RRA. No significant differences in cell numbers
were observed withthe differenttreatments. Thetimecourseplotted
is representative ofthree replicative experiments and three separate
cell isolates for each cell type.
tide As, or by a peptide mixture containing equivalent mo-
lar concentrations of lysine and arginine residues. Treatment
with peptide AL does not affect the secretion of another
constitutively produced growth modulator, transforming
growth factor-ß (TGF-ß; data not shown).
Peptide AL (200 ttg/ml) has no detectable effect on
HUVEC or SMC PDGF A or B-chain transcript levels 15
and 30 min, 1, 2, 4, 6, and 24 h after addition of peptide AL
(data not shown) . Neither addition of the peptide to cultures
at 4°C nor 3-h pretreatment of the cells with cycloheximide
blocks the early release ofPDGF in response to the addition
of peptide AL (Table I) . Transport from the RER and stimu-
lated exocytosis of secretory proteins are severely inhibited
below 20°C (Saraste et al., 1986) or by blocking protein syn-
thesis. Thus, these observations are consistent with the pos-
sibility that peptide AL may regulate the release of PDGF
from preformed storage pools. Interestingly, peptide AL-
induced release of PDGF does not require the PDGF recep-
tor to be active since PDGF is released from HUVEC (Figs.
2 and 3), which do not express PDGF receptors (Heldin et
al., 1981; Bowen-Pope and Ross, 1982 ; Smits et al., 1989).
Peptide AL also does not compete for binding to the PDGF
receptor on fibroblasts or SMC (data not shown) .
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TableL Cycloheximide and Decreased Temperature
Do Not Prevent Peptide-induced Release ofPDGF
HUVEC or SMC were cultured as described in Fig. 2. In experiment 1, the
cultures were treated with 5 jug/ml cycloheximide for 3 h before addition of
peptide AL. Protein synthesis, as determined by 'H-leucine incorporation
into TCA-precipitable protein, was inhibited by 80 and 93% in the HUVEC
and SMC cultures, respectively. In both experiments, the HUVEC cultures
were treated with 2.3 x 10-5 M peptide AL, and the SMC cultures with 9.2
x 10-' M peptide AL. The PDGF levels were determined by RRA and are
expressed as the mean ± SEM from three doses determined in triplicate.
These two experiments are representative of duplicate experiments.
Characterization ofthe Form ofPDGFReleased by the
Peptide Encoded by Exon 6 ofthe PDGFA-Chain
To determine which dimeric forms ofPDGF are released af-
ter treatment with peptide AL, chain-specific antibodies
(Hartet al., 1990; Ross et al., 1990) were used to evaluate
HUVEC- and SMC-conditioned media (Table II) . After
Table H. Dimeric Form ofPDGFReleased
after Treatment with the Peptide Encoding Exon 6
ofthe PDGF A-Chain (AL)
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Chain-specific ELISA RRA with "5I-AB
Antisera
PDGF assays
PDGF ELISA, using chain-specific antibodies or a PDGF RRA on human fibro-
blasts, were utilizedto evaluate the PDGF content ofmediacollectedfrom cells
treated with different concentrations ofpeptide AL. The chain-specific ELISAs
use a mAb made to recombinant PDGF-AA, 127.2.2.2 (Hart et al., 1990) or
a mAb toa 25-amino acidpeptidelocated neartheCOOH-terminus ofthe PDGF
B-chain, PGF-007 (Shiraishietal., 1989; Ross et al., 1990) incombinationwith
rabbit anti-PDGF antisera from animals immunized with either recombinant
PDGF-AA (aA) or PDGF-BB (aB) (Hart et al., 1990). Ifthe relative recogni-
tion of PDGF-AA and PDGF-BB is normalized to PDGF-AB (1.0), the signals
for PDGF-AA and PDGF-BB detected with the antibody 127.2.2.2 (aA) are
50 and NS; with antibody 007 (c:A) NS and 0.06; and with antibody 007 (all)
NS and 3.0. is5I-PDGF-AB was the radioligand for the PDGF RRA on human
dermal fibroblasts as previously described (Bowen-Pope and Ross, 1985). NS
indicates that no significant signal was detected.
Cell treatment Time
h
127 .2 .2 .2
(aA)
007
(aA)
ng1106
007
(ßB)
PDGF
HUVEC
none 24 0.32 0.28 7.8 0.82
diluent 4 0.04 0.02 0.12 0.17
1 x 10-sMAL 4 0.04 0.02 0.63 0.32
1 x 10-6 MAL 4 0.04 0.02 3.28 0.75
2.3 x 10-5 M AL 4 0.08 0.26 12.9 1.70
SMC
none 96 0.18 NS NS 0.4
diluent 4 NS NS NS NS
1 x 10-9 MAL 4 0.06 NS NS 0.14
PDGF,
HUVEC
ng/106 cells/2 h
SMC
Experiment 1
untreated 1.15 ± 0.23 0.15 ± 0.01
3 h cycloheximide 1.28 t 0.36 0.13 ± 0.03
Experiment 2
37C 0.64 1 0.01 0.10 ± 0.06
4°C 0.64±0.08 0.09±0.01Figure 4. Exon 6 peptides induce release of a larger form ofPDGF-
AA from smooth muscle cells and a larger form ofPDGF-BB from
HUVEC . (A ) Cultures of human SMC or HUVEC were treated
as described in Fig. 1, except at the time of initiation ofthe experi-
ment, the cultures were changed to serum-free medium (Hepes
buffered) and incubated with 2.3 x 10-5 M peptide AL for 4 h at
room temperature. The media were concentrated N200x (Centri-
prep concentrators, Amicon) and 5 pl analyzed per lane by SDS
Western blot analysis after separation on 15% SDS-PAGE as de-
scribed in Materials and Methods . The samples analyzed included
a thrombin release ofhumanplatelets, PDGF-BB isolated from hu-
man platelets (BB), recombinant PDGF-AA (AA), and the SMC
andHUVEC (HUV) medium concentrates from peptideAL-treated
cells . Samples were analyzed under nonreducing conditions . The
blots were incubated with the affinity-purified anti-PDGF, which
recognizes all chains ofPDGF. The molecularweights ofthe princi-
pal bands are shown on the right . (B) Cultures ofHUVEC were
metabolically labeled with "S-Cysteine for 16 h as described in
Materials and Methods . After a 2-h chase, replicate cultures were
treated for 4 h at 4° with either diluent or 8.3 x 10-5 M peptide
B2, . The cell layers were collected, incubated with anti-PDGF-BB
coupled to Sepharose in the presence (+) or absence (-) of unla-
beled PDGF-BB, and the immunoprecipitated species were ana-
lyzed by SDS-PAGE under reducing conditions followed by auto-
radiography. Immunoprecipitation of mature 'BSI-PDGF-BB is
shown for comparison .
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treating HUVEC with peptide AL, most of the increase in
PDGF is detected with the B chain-specific antibody PGF-
007 (Shiraishi et al ., 1989 ; Ross et al ., 1990) and with a sec-
ond antibody that is also specific for the B-chain (Hart et al .,
1990) . In contrast, SMC appear to release principally
PDGF-AA after treatment with peptide AL .
The nature of the dimeric forms ofPDGF released by pep-
tide AL was further analyzed by Western blot (Fig . 4 a) .
Using an affinity-purified goat polyclonal anti-PDGF IgG
that recognizes all three dimeric forms ofPDGF (Raines et
al ., 1989), species with "24,000, 35-42,000, and greater
than 100,000 M, were detected under nonreducing condi-
tions in the HUVEC media after treatment with peptide AL .
The species >100,000 and 35-42,000M r are larger than the
mature protein (ti27-31,000) (Fig . 4 a) . The 35-42,000-D
species is consistent with the estimated size of the precursor
B-chainmolecule, which contains sequence encodedby exon
6 but lacks the NHz terminal "pro" sequence (Igarashi et
al ., 1987) . After reduction, the principal species present in
the HUVEC media are also larger than the mature B-chain
protein (data not shown) . Analysis of the PDGF species
released into the medium by SMC treated with peptide AL
also demonstrates principally M species greater than ma-
ture PDGF-AA : a band at "24,000 D, a doublet at 35,000
D, and multiple bands larger than 100,000 D under non-
reducing conditions (Fig . 4 a) . While the 35-42,000-D spe-
cies from endothelial cells and 35,000-D species from SMC
are consistent with the expected size of forms containing
exon 6, the identity of the larger and smaller forms will re-
quire analysis with sequence-specific antisera .
The nature of the cell-associated forms ofPDGF was also
analyzed in HUVEC after labeling with "S-Cysteine (Fig .
4 b) . Immunoprecipitates of diluent-treated cells contained
18000- and 20,000-D species after reduction that were not
detected in cells treated with peptide Bu , a peptide homol-
ogous with peptide AL encoded by exon 6 of the B-chain
(Fig. 1 a), for 4 h at 4°. These species are again consistent
with the estimated size of the precursor B-chain molecules
which contain sequence encoded by exon 6 but lack the
N112-terminal "pro" sequence (Igarashi et al ., 1987) . They
are also larger than the 14,000- and 16,000-D chains ob-
served in mature forms of PDGF-BB (Fig. 4 b) . Further-
more, these studies establish that the PDGF released by ad-
dition of the peptide encoded by exon 6 is synthesized by the
cells.
PeptidesEncoded by Exon 6 ofEither theA- or B-
Chain ofPDGF Induce Release ofPDGFandBind to
Extracellular Binding Sites
Since peptide AL induced the release of principally higher
molecular weight species of both PDGF-AA andPDGF-BB,
depending on the cell type (Fig . 4), we hypothesized that
peptide AL was competing for a cell binding site for the se-
quence encoded by exon 6 that is shared by the000H termi-
nus of the long form of the A-chain and by precursors of the
B-chain that contain the COOH-terminal "pro" sequences
encoded by exon 6 ofthe B-chain (Fig . 1 a) . Ifthis were true,
the homologous sequence encoded by exon 6 of the B-chain
should also be able to induce release ofPDGF As shown in
Table III, two peptides containing different portions of the
B-chain exon 6 sequence also induce release ofPDGF from
537TableIII. Peptides Encoded by Exon 6 of
the PDGFB-Chain Also Induce Release ofPDGF
from Human SMC and HUVEC
Cultures of human SMC and HUVEC were prepared as described in Fig. 2 and
incubated for 4 h in the presence of 2 x 10-5 M of the indicated peptides.
Peptides AL, B24, and B6 are shown in Fig. 1 . The levels of PDGF were de-
termined by PDGF RRA.
endothelium and smooth muscle. Each of the B-chain pep-
tides contains a number of basic amino acids and contains
sequences homologous to the peptide encoded by exon 6 of
the A-chain (Fig. 1 a). Addition ofrandomized peptides con-
taining the same amino acids as the exon 6 peptides, but with
the basic amino acids alternating with nonbasic amino acids
(YRGKPRVKTRSKGRPKVRTK and YRGKPRVKTRSR-
GRP), did not induce release of PDGF (data not shown).
To further determine whether thepeptide encoded by exon
6 is involved in the binding of larger forms of PDGF to cells,
we synthesized these peptides with an added NH2-terminal
tyrosine residue to facilitate '251 binding studies. The pep-
tide sequences encoded by exon 6 of the A- and B-chain bind
specifically to both HUVEC (Fig. 5 a) and SMC (Fig. 5 b).
The estimated KD ofbinding for each peptide is 2-4 x 10-6,
and the estimated number of binding sites is 4-8 x 109 for
endothelial cells and 1 x 101 for SMC. Randomized pep-
tidescontaining the same number ofbasic residues also bind
to HUVEC and SMC with a comparable number of binding
sites and binding affinity (data not shown) . However, exon
6 B-chain peptides or randomized peptides were 10-30-fold
less effective than peptide AL in competing for 1251-peptide
AL binding (Fig. 6 a).
The large number of binding sites and the basic nature of
the peptides are consistent with the possibility that the exon
6 sequences might bind to HS-PG. This possibility is sup-
ported by the ability of heparin and heparan sulfate, but not
chondroitin sulfate A, B, or C, to compete for binding of
peptide AL to HUVEC (Fig. 6 b). The exon 6 peptides also
bind to extracellular matrix as shown by extraction with 4 M
urea (Fig. 6, c and d) . Similar relative competition can be
observed with the B-chain peptides and the randomized pep-
tide in the cell-associated and extracellular matrix competi-
tion studies (Fig. 6, a and c) . Involvement of HS-PG in both
the cell-associated and extracellular matrix binding is sug-
gested by the observation that heparin and heparan sulfate
compete for binding, while chondroitin sulfate A, B, and C
do not compete at the concentrations tested (Fig. 6, b and d).
Similar relative competition with peptides and glycosamino-
glycans was observed with human SMC (data not shown).
A role for the HS-PG in exon 6 binding is further sup-
ported by affinity cross-linking studies (Fig. 7). Peptide AL
and peptide B6 were bound and cross-linked as high molec-
ular weight complexes on human SMC. Even with a 5
separating gel, the high molecular weight complexes did not
enter the separating gel (suggesting a molecular weight
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Figure S. Peptides representing exon 6 of the PDGF A- and PDGF
B-chain bind specifically to human SMC and HUVEC. Saturation
binding analysis of '251-peptide AL (9) and 1251-peptide B6 (o) to
HUVEC (A) or human carotid SMC (B). The results are plotted
as the number of specifically bound 1251-labeled ligand molecules/
cell at each concentration tested, andrepresent the average ofdupli-
cate determinations. Nonspecific binding, determined at 5 x 10-8
and 5 x 10-'M, averaged 11.5 and 16% of total bound counts on
SMC, and 6.2 and 7.5% oftotalboundcounts on HUVEC for pep-
tide AL and peptide B6, respectively.. The inset shows the binding
data plotted according to the method of Scatchard (1949). In the
Scatchard plot of the data, bound/free is x 1015 for HUVEC and
x1013 for SMC.
greater than 300,000 D) . Treatment of the membrane-asso-
ciated material with heparinase before separation on SDS-
PAGE significantly reduced the radioactivity associated with
the complex. The high molecular weight complex that did not
enter the 5 % separating gel was not observed in the presence
of excess unlabeled peptide. Further characterization of this
high molecular weight complex on agarose gels and 3-12
gradient gels suggests that the exon 6 peptide is bound to hy-
drophobic HS-PG (Raines, E. W., E. Sch6nherr, M. Kin-
sella, T. N. Wight, and R. Ross, unpublished observations).
ModelofProposedCompartmentalizationofPDGF
ContainingExon-6-Specific Sequences
A model depicting the proposed interactions between the
PDGF, ng/106 cells
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M
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exon-6-coded peptides and HUVEC or SMC is shown in Fig.
8. This report demonstrates that, when added to cultured
HUVEC or SMC, the peptide AL induces a rapid, dose-
dependent, temperature-independent release of PDGF into
the culture medium. PDGF release is specific to the se-
quences encoded by exon 6 ofthe A- and B-chains. Depend-
ing on the cell type, most of the PDGF-AA or PDGF-BB
released by exposure to peptide AL exhibited apparent mo-
lecular weight larger than the mature proteins, consistent
with the expected size of the long form of the A-chain, or
precursor form of the B-chain containing exon-6-encoded
sequences. The peptides encoded by exon 6 ofPDGF A- and
B-chains bind specifically to a relatively large number of
low-affinity binding sites present on cultured HUVEC and
SMC. Characterization of these binding sites by competition
studies, and analysis of cross-linked species, are consistent
with the association of the exon-6-encoded basic residues
with HS-PG on the cell surface and in the extracellular ma-
trix . Thus, we hypothesize that transcription and translation
of exon 6 of the A or B-chain of PDGF can result in these
forms of PDGF remaining cell and/or matrix associated. As-
sociation of PDGF with the HS-PG would depend on the
presence of the exon-6-encoded sequence in the secreted
PDGF as well as expression of the HS-PG. Localization of
pro-PDGF-BB (the form that contains the exon-6-encoded
sequence) on such extracellular binding sites could also be
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Figure 6. Competition bind-
ing studies with peptides re-
lated to peptide-AL and gly-
cosaminoglycans on HUVEC.
Competition studies were per-
formed with peptides related
to peptide-AL (A and C) or
glycosaminoglycans (Band D).
The indicated molar concen-
trations of peptide-AL (0),
peptide B24 (À) and Bs (o),
and a randomized peptide, AR
(o), containingthe same num-
beroflysine and arginine resi-
dues as AL, were incubated
with HUVEC for 3 h at 4°C
with shaking (A and C). Al-
ternatively, HUVEC were in-
cubated with purified glycos-
aminoglycans heparin (o),
heparan sulfate (o), chondroi-
tin sulfates, type A (o), type
B (A), and type C (o) for 3 h
at 4°C (B and D) . After 3 h,
î25I-peptide-AL was added and
incubated for an additional 1 h
at4°C. Cells were washed and
first membrane-associated pep-
tide was solubilized with 1%
Triton X-100 in H2O (A and
B) and then matrix-associated
peptide (C and D) was ex-
tracted with 4M urea in PBS.
The sequence of the random-
ized peptide AR is YRGKPR-
VKTRSKGRPKVRTK.
altered by the presence of enzymes capable of cleaving the
COOH-terminal "pro" sequence containing the exon 6 bind-
ing sequence to release mature PDGF-BB (Fig. 8) . En-
zyme(s) may cleave the long form of the A-chain at multiple
mono-, di-, and polybasic cleavage sites (Fisher and Scheller,
1988) within the exon-6-encoded sequence and therefore re-
lease a cleaved form of PDGF-ALAL from the cell surface
(Fig. 8). It is also possible that release of heparanases from
platelets and neutrophils (Vlodavsky et al ., 1991) and hepa-
rin from mast cells(Fransson, 1985), may also regulate solu-
ble and diffusible forms of exon 6 containing PDGF mole-
cules.
It is unclear why subcutaneous injection of the exon 6
sequence in rabbits induced antibodies to different forms
of PDGF and the unrelated As sequence. However, we hy-
pothesize that the peptide may induce release of PDGF from
epidermal cells in the skin which stain strongly immunohis-
tochemically with PDGFRB-specific antibodies (Sasahara,
M., E. W Raines, and R. Ross, unpublished observations) .
Examination of the mechanism of action of the peptide in
vivo will be necessary to determine whether the peptides
may possibly be useful clinically to alter the delivery of
PDGF; to promote release ofendogenous PDGF in a diffus-
ible form; or even to develop antibodies to PDGF in certain
patient populations.Figure 7 . Characterization of the exon-6 binding site . Affinity-
labeled and cross-linked "I-peptide-AL complexes and 125I-peptide-
B6 complexes isolated from human SMC were analyzed by SDS-
PAGE . Human SMCs were incubated with 5 x 10-7M 125I-peptide
AL or 12'I-peptide B6 for 3 h at 4°C in the presence or absence of
unlabeled peptide AL or B6 . After washing to remove unbound
peptide, peptide bound to the cells was cross linked with 1 mM Bis
(sulfosuccinimidyl) suberate (Pierce Chemical Co .) for 5 min at
4°C, washed, and then cross-linked complexes were solubilized in
SDS sample buffer. Prior to separation on 5% SDS-PAGE, some
samples were incubated with heparinase for 2 h at 37°C . î 25I-pep-
tides not incubated with cells were also separated by SDS-PAGE .
The arrowhead indicates the separating gel interface and the arrow,
the migrationposition of free peptide. Nonspecific binding forpep-
tides AL andB6 was 2 .1 and 6.3% of total bound and cross-linked
counts . All samples were run in the presence of5% mercaptoetha-
nol added priortoboiling and loading onthe gels . Molecularweight
standards are indicated on the right .
The SequenceEncoded by Exon 6ofPDGFA- and
B-Chain Is Extremely Basic
The sequences encoded by exon 6 of the PDGF A- and
B-chains share only 28-50% homology, depending on the
alignment and the number of residues included . However,
they each contain a large number of basic amino acids. A
number ofunique properties have been ascribed to such high
local concentrations of basic amino acids . Polylysine-con-
taining peptides, including the COON-terminal segment of
the human c-Ki-ras 2 protein, affect membrane protein ki-
nases, phosphatidylinositol kinases, and adenylate cyclase
(Gatica et al., 1987 ; FujitaYamaguchi et al ., 1989), and the
Lys-Arg-Lys-Arg sequence found in exon 6 of PDGF-B but
not PDGF-A is found in melittin and can inhibit adenylate
cyclase (Cook and Wolff, 1977) . Specific sequences within
exon 6 ofPDGF-A and PDGF-B have been demonstrated to
encode nuclear targeting signals (Lee et al ., 1987 ; Maher et
al ., 1989) . Basic sequences, including those of FGF and
platelet factor-4, have been associated with increased cell
adhesion, protein-glycosaminoglycan interactions, and inhi-
bition of angiogenesis (Rideout et al ., 1985 ; Baird et al.,
1988 ; Cardin and Weintraub, 1989 ; Maione et al ., 1990) .
Another family of molecules, the ras proteins, also contains
a polybasic domain . Such a domain, together with palmitoy-
lation and farnesylation hasbeen demonstrated to beessential
for plasmamembrane targeting (Hancock et al ., 1990) . Inves-
tigation ofsuch possible interactions may reveal localizations
and biological activities of PDGF "precursors" containing
exon 6 as well as possible activities ofreleased free peptide .
It is interesting to note that the basic sequence encoded by
exon 6 and alternative splicing of exon 6 is conserved in the
PDGF-relatedprotein, vascular endothelial growth factor, or
vascular permeability factor (Keck et al ., 1989 ; Leung et al .,
1989 ; Tischer et al ., 1989 ; Betsholtz et al., 1990) . Exon 6
of vascular endothelial growth factor/vascular permeability
factor codes for6 of the 7 consecutivebasic residues encoded
by exon 6 of the A-chain (KKRKRKR) with the sequence
reversed (KRKRKK) . We hypothesize that the long form of
vascular endothelial growth factor/vascular permeability
factor may also be localized extracellularly, depending on
peptide binding sites and processing enzymes .
Figure 8 . Model of proposed
compartmentalizationofPDGF
containing exon-6-specific se-
quences . We hypothesize that
translation of exon 6 of the
A or B-chain ofPDGF results
in selective compartmentali-
zation of these forms ofPDGF
(PDGF-ALAL and "pro-PDGF-
BB") on cell- and matrix-asso-
ciated HS-PG. However, the
alternatively spliced form of
PDGF A-chain (PDGF-A sAs),
lacking exon-6-encoded se
quences would not bind to HS-PG and would therefore be secreted and diffusable. Addition of competing peptide (as shown in this report)
or enzymes capable of cleaving the COOH-terminal exon 6 binding region could also result in increased levels of soluble PDGF. Such
differential compartmentalization may provide a means whereby PDGF can act as a growth factor involved in either cell-cell interactions
or targeting PDGF-producing cells to tissue sites rich in PDGF receptors, or in a broader context as a paracrine growth factor.
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Studies of cells transfected with the PDGF B-chain-
homologues p285î5 or with PDGF B-chain have suggested
that most of the active PDGF-BB remains membrane as-
sociated, whereas cells transfected with PDGF-AA release
most of the PDGF into the medium (Robbins et al., 1985;
Johnsson et al., 1985 ; Igarashi et al., 1987; Stevens et al .,
1988; Bywater et al., 1988 ; Beckmann et al., 1988 ; Lokesh-
war et al., 1990). No obvious structural motifs, such as hy-
drophobic stretches that might cause retention of PDGF-BB,
have been observed. Recent experiments with PDGF-A and
-B chimeric molecules correlated the presence of the last 13
residues of exon 6 with membrane localization (LaRochelle
et al., 1990). Smaller dimeric forms of PDGF-BB (30, 24,
and 21 kD), lacking exon 6 sequences, have also been
identified in membrane fractions after metabolic labeling of
transfected cells (Robbins et al., 1985; Stevens et al., 1988;
Bywater et al., 1988) . It is, therefore, possible that other se-
quences in the mature protein, or protein modification, such
as isoprenylation (Maltese, 1990) may also be involved in
cell association by different forms of PDGF-BB.
TheLongandShortFormsofPDGF-AA
Although PDGF-AL and PDGF-As arise from alternative
splicing of exon 6 and differ only in their COON-terminal
sequence (Fig. 1), both proteins are biologically active (Col-
lins et al., 1987; Beckmann et al., 1988; Bywater et al.,
1988; Ostman et al., 1989). They were originally observed
in human tumor cellsand HUVEC(Collins et al., 1987; Bet-
sholtz et al., 1986; Tong et al., 1987; Rorsman et al., 1988) .
However, Xenopus oocytes also synthesize both forms of the
A-chain mRNA (Mercola et al., 1988). Examination ofnor-
mal tissues has demonstrated expression of both A-chain
transcripts, with the short form being the predominant spe-
cies (Matoskova et al., 1989; Young et al., 1990). Expres-
sion of PDGF-ALAL and PDGF-AsAs in Saccharonryces
cerevisiae has allowed more detailed comparisonofthe bind-
in$ and mitogenic properties of each form of the A-chain
(Ostman et al., 1989) . No significant differences were de-
tected in binding specificity, binding affinity, or mitogenic
potency between PDGF-AsAs and PDGF-ALAL. Rather than
differing in biological activity, our observations suggest that
the exon-6-containing form of the A-chain remains cell as-
sociated, whereas the spliced form is secreted.
In previous metabolic labeling studies of NIH-3T3 cells
transfected with the long or short forms of the PDGF
A-chain, no differences in the cellular compartmentalization
of PDGF-AL and PDGF-As were detected, although the ex-
pression levels were at least 20-fold higher with the long
form of the A-chain (Beckmann et al., 1988). In addition,
when PDGF-A and -B chimeric molecules were expressed
in the same cells, the presence of exon 6 sequences of either
the A- or the B-chain demonstrated roughly comparable lev-
els of PDGF immunoreactive protein in crude membrane
preparations. Only chimeras containing exon 6 oftheA-chain
were efficiently secreted (LaRochelle et al., 1990). Although
these observations appear to be contrary to the hypothesis
proposed in this study, the possible role of enzymes capable
of releasing the mature forms (Fig. 8) is supported by a re-
cent study using inhibitors of proteolysis (LaRochelle et al.,
1991). Monensin treatment of cells transfected with the long
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form of PDGF A-chain blocked secretion and proteolytic
processing of PDGF A-chain. Cell-surface-retained PDGF
A-chain could be released by treatment with suramin in a
manner indistinguishable from that of cell-surface-retained
PDGF B-chain. Our hypothesis is further supported by ob-
servations in the RAT-1 cell line in which transfectants ex-
pressing the short form of PDGF-AA secreted several fold
more immunoreactive PDGF-like protein than the long form
of PDGF-AA, containing the exon-6-encoded sequences, in
spiteofsimilar mRNA levels (Bywater et al., 1988) . Coinci-
dent with our studies, analysis of transfectants of PDGF
B-chain in COS cells identified sequences within exon 6 of
the A- and B-chain that appear to mediate cell association
(Östman et al., 1991) . The regions identified in both the
LaRochelle (1991) and Östman (1991) studies are the same
as those identified in this study. It is most likely that differ-
ences between the different cell expression systems previ-
ously reported represent variations in expression levels of
PDGF, HS-PG, processing enzymes, or combinations of
these factors.
CellandMatrix AssociationMay FocusandProlong
theActivity ofGrowth Factors
Both cell and matrix association of growth factors suggests
the existence of several possibly important regulatory mech-
anisms. A number of growth-regulatory molecules, includ-
ing EGF (Gray et al ., 1983; Scott et al., 1983), transforming
growth factor-a (Brachmannet al., 1989; Wong et al., 1989;
Anklesariaet al., 1990; Teixido etal., 1987; 1990), vaccinia
growth factor (Stroobant et al ., 1985), colony-stimulating
factor (Rettenmier et al ., 1987), and tumor necrosis factor-a
(Kriegler et al., 1988) are produced as part of membrane-
anchored precursors that may interact with receptors.on the
surface of adjacent cells. In each of these cases, proteolytic
processing of these membrane precursors generates soluble
factors. This is not always an efficient process and can lead
to local accumulation. It has been hypothesized that such
membrane-associated growth factors may not only be active,
but may prolong the biological response as compared with
soluble, diffusible factors. Differentiation inhibiting activity,
a factor that specifically inhibits embryonic stem cell dif-
ferentiation, has been shown to be produced through alter-
native transcripts as a diffusible protein and in an immobi-
lized form associated with the matrix (Rathjen et al., 1990) .
Other growth factors, such as FGF (Baird et al., 1987;
Vlodavsky et al., 1987; Folkman et al ., 1988; Saksela et al.,
1988; Saksela and Rifkin, 1990), TGF-ß (Andres et al.,
1989), and granulocyte-macrophage colony-stimulating fac-
tor (Gordon et al., 1987; Roberts et al., 1988) have also been
shown to associate with specific matrix constituents, primar-
ily HS-PG. These matrix-associated forms have been pro-
posed to participate in functions such as localized retention,
protection from proteolytic degradation, delivery, and clear-
ance. Enzymes can release these "stored" growth regulatory
molecules. Although it is not known whether cell-associated
PDGF is active, a number of the same possibilities couldbe
proposed for the exon-6-derived forms of PDGF. The short
form of the Achain, or exon 6 containing forms of PDGF
in which the exon 6 sequence is removed by enzymes, would
be secreted and able to diffuse and stimulate cellsbeyond the
local environment. PDGF with exon 6 sequences, however,
54 1would be immobilized and confined to specific sitescontain-
ing HS-PG. Such interactions may be important in develop-
mental and repair processes that depend on specific cell-cell
interactions or targeting PDGF-producing cells to tissue
sites rich in PDGF receptors.
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